Does your background affect your MS treatment? new study investigates

NCT ID NCT05131984

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed medical records of 800 multiple sclerosis patients to see if gender, race, or socioeconomic status affected how quickly they started Ocrelizumab or how well it worked. Researchers looked at relapse rates and MRI changes over 12 to 24 months. The goal was to identify any differences in treatment access and outcomes among diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.